VRTX Vertex Pharmaceuticals Inc

Price (delayed)

$237.59

Market cap

$61.78B

P/E Ratio

22.93

Dividend/share

N/A

EPS

$10.36

Enterprise value

$56.97B

Sector: Healthcare
Industry: Biotechnology

Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather ...

Highlights

The gross profit has soared by 68% YoY and by 11% from the previous quarter
VRTX's revenue has soared by 66% YoY and by 11% QoQ
VRTX's debt is down by 10% YoY but it is up by 4.7% QoQ

Key stats

What are the main financial stats of VRTX
Market
Shares outstanding
260.04M
Market cap
$61.78B
Enterprise value
$56.97B
Valuations
Price to earnings (P/E)
22.93
Price to book (P/B)
7.61
Price to sales (P/S)
10.33
EV/EBIT
19.24
EV/EBITDA
18.57
EV/Sales
9.51
Earnings
Revenue
$5.99B
EBIT
$2.96B
EBITDA
$3.07B
Free cash flow
$2.98B
Per share
EPS
$10.36
Free cash flow per share
$11.44
Book value per share
$31.23
Revenue per share
$23.01
TBVPS
$38.02
Balance sheet
Total assets
$11.3B
Total liabilities
$3.17B
Debt
$546.51M
Equity
$8.13B
Working capital
$5.45B
Liquidity
Debt to equity
0.07
Current ratio
3.72
Quick ratio
3.46
Net debt/EBITDA
-1.57
Margins
EBITDA margin
51.2%
Gross margin
88%
Net margin
44.9%
Operating margin
44.7%
Efficiency
Return on assets
27.8%
Return on equity
38.2%
Return on invested capital
101.3%
Return on capital employed
31.8%
Return on sales
49.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

VRTX stock price

How has the Vertex Pharmaceuticals stock price performed over time
Intraday
-0.44%
1 week
5.34%
1 month
1.15%
1 year
1.27%
YTD
0.53%
QTD
0.53%

Financial performance

How have Vertex Pharmaceuticals's revenue and profit performed over time
Revenue
$5.99B
Gross profit
$5.27B
Operating income
$2.68B
Net income
$2.69B
Gross margin
88%
Net margin
44.9%
The operating margin has soared by 108% YoY and by 15% QoQ
The gross profit has soared by 68% YoY and by 11% from the previous quarter
VRTX's revenue has soared by 66% YoY and by 11% QoQ
Vertex Pharmaceuticals's net income has increased by 29% QoQ and by 25% YoY

Growth

What is Vertex Pharmaceuticals's growth rate over time

Valuation

What is Vertex Pharmaceuticals stock price valuation
P/E
22.93
P/B
7.61
P/S
10.33
EV/EBIT
19.24
EV/EBITDA
18.57
EV/Sales
9.51
The price to earnings (P/E) is 39% less than the last 4 quarters average of 37.8
The EPS has increased by 29% since the previous quarter and by 23% year-on-year
The equity has soared by 55% YoY and by 8% from the previous quarter
The stock's price to book (P/B) is 49% less than its 5-year quarterly average of 14.8 and 19% less than its last 4 quarters average of 9.4
VRTX's revenue has soared by 66% YoY and by 11% QoQ
The price to sales (P/S) is 27% less than the 5-year quarterly average of 14.1 and 21% less than the last 4 quarters average of 13.0

Efficiency

How efficient is Vertex Pharmaceuticals business performance
The return on sales has surged by 113% year-on-year and by 17% since the previous quarter
The return on invested capital rose by 27% since the previous quarter
VRTX's return on assets is up by 17% since the previous quarter but it is down by 11% year-on-year
The return on equity has grown by 16% since the previous quarter but it has declined by 13% year-on-year

Dividends

What is VRTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for VRTX.

Financial health

How did Vertex Pharmaceuticals financials performed over time
Vertex Pharmaceuticals's total assets has surged by 50% YoY and by 11% QoQ
The total liabilities has increased by 40% YoY and by 17% QoQ
VRTX's debt is 93% lower than its equity
The equity has soared by 55% YoY and by 8% from the previous quarter
VRTX's debt is down by 10% YoY but it is up by 4.7% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.